EGFR and adenocarcinoma: The higher frequency of adenocarcinoma-associated FGFR fusions and the higher frequency of co-existing EGFR sensitizing and EGFR resistant mutations in the GH electronic database may both reflect the higher proportion of cases with acquired resistance to targeted treatments included in the GH database, which, in turn, reflects real-world referral patterns for liquid biopsy testing after disease progression on prior therapies.